"""
Question: 1101 

Evidence: Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7).

Rationale: The study prospectively enrolled participants and reports original clinical outcomes, pharmacokinetics, and resistance findings over 48 weeks following a regimen switch, indicating previously unpublished data generated by this study.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Past HIV-RNA genotypes showed a B subtype with the presence of K103N and 100I mutations. One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H).

Rationale: The paper mentions resistance mutations and subtypes from genotypes but does not provide actual sequence data or accession numbers; it reports mutation summaries rather than reporting HIV sequences.

Answer: No
"""

"""
Question: 1103 

Evidence: Patients … were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Clinical data, pVLs and safety parameters, including adverse events (AEs), were collected at baseline … W4, W12, W24 and W48.

Rationale: The study is clinical/observational with pharmacokinetics and resistance genotyping; there is no description of laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Secondary outcomes included … plasma drug concentrations and resistance profile in the case of VF. Plasma concentrations of etravirine and raltegravir were determined by UPLC coupled with tandem MS.

Rationale: The study reports pharmacokinetics and genotypic resistance but does not perform or report in vitro antiretroviral susceptibility testing.

Answer: No
"""

"""
Question: 2101 

Evidence: Past HIV-RNA genotypes showed a B subtype … The integrase gene had not been sequenced on past genotypes, and no sample was available to perform genotyping before the VF.

Rationale: Although genotypes and mutations are described, there are no GenBank accession numbers reported anywhere in the paper.

Answer: No
"""

"""
Question: 2102 

Evidence: Past HIV-RNA genotypes showed a B subtype … Viral resuppression was achieved on dolutegravir/rilpivirine (50/25 mg q24h) + lamivudine (300 mg q24h).

Rationale: The paper provides mutation summaries but no deposited sequence identifiers; therefore, no GenBank accession numbers for any isolates are reported.

Answer: No
"""

"""
Question: 2103 

Evidence: Past HIV-RNA genotypes showed a B subtype … The integrase gene had not been sequenced on past genotypes, and no sample was available to perform genotyping before the VF.

Rationale: No accession numbers are presented in the text; only mutation-level summaries are provided.

Answer: NA
"""

"""
Question: 2202 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H). Past HIV-RNA genotypes … with several NNRTI-associated resistance mutations (A98G, K101R and G190E/Q).

Rationale: The paper lists specific mutations for individual cases (the two VF cases), corresponding to mutation lists for individual isolates.

Answer: Yes
"""

"""
Question: 2301 

Evidence: All HIV-1-infected adults ≥18 years old … were eligible in this prospective cohort study.

Rationale: The study specifically targeted HIV-1-infected adults.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Past HIV-RNA genotypes showed a B subtype … The patient … The second VF … Past HIV-RNA genotypes displayed an A1 subtype.

Rationale: Subtype B is reported for one individual and subtype A1 for another, indicating the subtypes of the sequenced viruses referenced.

Answer: Subtype B; Subtype A1
"""

"""
Question: 2303 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H). Past HIV-RNA genotypes … with several NNRTI-associated resistance mutations (A98G, K101R and G190E/Q).

Rationale: INSTI-associated mutations map to the integrase gene; NNRTI-associated mutations are in reverse transcriptase. Thus, integrase and reverse transcriptase (both in pol) were sequenced.

Answer: Integrase; Reverse transcriptase
"""

"""
Question: 2304 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H). Past HIV-RNA genotypes … with several NNRTI-associated resistance mutations (A98G, K101R and G190E/Q).

Rationale: The reported mutations are within the pol gene regions (integrase and reverse transcriptase), indicating results from HIV pol sequencing.

Answer: Yes
"""

"""
Question: 2401 

Evidence: … were eligible in this prospective cohort study conducted in seven clinical sites in France.

Rationale: The sequences/mutations reported arose from patients enrolled at sites in France.

Answer: France
"""

"""
Question: 2402 

Evidence: Between September 2017 and June 2018, 113 patients from seven French sites were screened. One VF occurred at W24 … The second VF occurred at W48 …

Rationale: The study screening period is provided, but the exact calendar years of the specific sequenced VF samples are not explicitly stated beyond visit weeks; therefore the precise years cannot be determined from the text.

Answer: NA
"""

"""
Question: 2502 

Evidence: Secondary efficacy endpoints included: the incidence of genotypic resistance … in the case of VF. Past HIV-RNA genotypes showed …

Rationale: The paper does not describe the sequencing platform or method (e.g., Sanger), so the method cannot be determined.

Answer: NA
"""

"""
Question: 2503 

Evidence: Secondary efficacy endpoints included: the incidence of genotypic resistance … in the case of VF. Past HIV-RNA genotypes showed …

Rationale: There is no mention of next-generation sequencing technology, so this cannot be determined from the text.

Answer: NA
"""

"""
Question: 2504 

Evidence: Secondary efficacy endpoints included: the incidence of genotypic resistance … in the case of VF. Past HIV-RNA genotypes showed …

Rationale: There is no mention of cloning prior to sequencing anywhere in the methods or results.

Answer: NA
"""

"""
Question: 2505 

Evidence: Secondary efficacy endpoints included: the incidence of genotypic resistance … in the case of VF. Past HIV-RNA genotypes showed …

Rationale: Single-genome sequencing is not mentioned or described.

Answer: NA
"""

"""
Question: 2506 

Evidence: Secondary efficacy endpoints included: the incidence of genotypic resistance … in the case of VF. Past HIV-RNA genotypes showed …

Rationale: Molecular cloning is not described in the study.

Answer: NA
"""

"""
Question: 2601 

Evidence: Past HIV-RNA genotypes showed a B subtype … One VF occurred at W24 … leading to the emergence of resistance mutations …

Rationale: The paper reports HIV-RNA (plasma) genotypes and resistance emergence during VF, indicating plasma HIV sequencing results.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Past HIV-RNA genotypes showed … The integrase gene had not been sequenced on past genotypes …

Rationale: The sequencing discussed pertains to HIV-RNA (plasma) genotypes; there is no report of PBMC/proviral DNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations … The second VF occurred at W48 … and no emergence of resistance.

Rationale: Resistance genotyping results are described for two plasma VF samples, implying two plasma sequencing events reported.

Answer: 2
"""

"""
Question: 2604 

Evidence: Past HIV-RNA genotypes showed … One VF occurred at W24 … The second VF occurred at W48 …

Rationale: Only HIV-RNA (plasma) genotypes are described; there is no PBMC sequencing reported.

Answer: 0
"""

"""
Question: 2605 

Evidence: One VF occurred at W24 with two pVL values of 7950 and 5440 copies/mL … leading to the emergence of resistance mutations associated with INSTIs.

Rationale: Sequencing at the time of high plasma viral loads indicates sequences were obtained during active HIV replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Past HIV-RNA genotypes showed … The integrase gene had not been sequenced on past genotypes …

Rationale: Sequencing reported is of HIV-RNA (plasma); there is no indication of sequencing from proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: All HIV-1-infected adults ≥18 years old … were eligible in this prospective cohort study.

Rationale: Only adults were included; no infants/children.

Answer: No
"""

"""
Question: 2702 

Evidence: … were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study.

Rationale: Participants were enrolled in a prospective interventional study, i.e., a clinical trial-like single-arm study.

Answer: Yes
"""

"""
Question: 2703 

Evidence: All HIV-1-infected adults ≥18 years old … were eligible … leaving 111 patients for analysis.

Rationale: All 111 analyzed participants were part of this single-arm study.

Answer: Yes
"""

"""
Question: 3101 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations … The second VF occurred at W48 … and no emergence of resistance.

Rationale: Resistance genotyping is only described for the two VF cases; thus two individuals had samples obtained for sequencing.

Answer: 2
"""

"""
Question: 3102 

Evidence: One VF occurred at W24 … The second VF occurred at W48 … Past HIV-RNA genotypes showed …

Rationale: Only the VF cases had sequencing reported in this study; therefore not all participants underwent sequencing.

Answer: No
"""

"""
Question: 4101 

Evidence: They were virologically suppressed on ART for a median duration of 7.9 years (IQR 5.9–10.7). 

Rationale: All participants were ART-experienced and suppressed; no ART-naive sequencing is reported.

Answer: No
"""

"""
Question: 4102 

Evidence: They were virologically suppressed on ART for a median duration of 7.9 years … Both had past NNRTI mutations.

Rationale: The sequences/mutations reported are from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: They were virologically suppressed on ART for a median duration of 7.9 years … One VF occurred at W24 … The second VF occurred at W48 …

Rationale: Only ART-experienced individuals are described; no ART-naive individuals were sequenced.

Answer: No
"""

"""
Question: 4104 

Evidence: They were virologically suppressed on ART for a median duration of 7.9 years … One VF occurred at W24 … The second VF occurred at W48 …

Rationale: No ART-naive individuals were included; hence no samples from ART-naive persons.

Answer: 0
"""

"""
Question: 4105 

Evidence: Participants' baseline characteristics are shown … The median duration of raltegravir/etravirine q12h was 29 months (IQR 26–40).

Rationale: The paper provides limited regimen duration data and selected prior genotypes, but not complete ART histories for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: All HIV-1-infected adults … virologically suppressed on ART … were eligible. Secondary efficacy endpoints included … the incidence of genotypic resistance … in the case of VF.

Rationale: The study does not assess population-level prevalence of transmitted drug resistance; it focuses on maintenance therapy and VF cases.

Answer: No
"""

"""
Question: 4202 

Evidence: All HIV-1-infected adults … virologically suppressed on ART … were eligible. Secondary efficacy endpoints included … the incidence of genotypic resistance … in the case of VF.

Rationale: The study population was treated and suppressed; there is no assessment of pretreatment (baseline, ART-naive) drug resistance prevalence.

Answer: No
"""

"""
Question: 4301 

Evidence: … switched … to a once-daily regimen given as etravirine 400 mg q24h … plus raltegravir 800 mg q24h. The patient was resuppressed under a dual therapy combining etravirine … and darunavir/ritonavir (800/100 mg q24h). Viral resuppression was achieved on dolutegravir/rilpivirine (50/25 mg q24h) + lamivudine (300 mg q24h).

Rationale: Reported regimens include NNRTIs (etravirine, rilpivirine), INSTIs (raltegravir, dolutegravir), a PI (darunavir/ritonavir), and an NRTI (lamivudine).

Answer: NNRTIs, INSTIs, PIs, NRTIs
"""

"""
Question: 4302 

Evidence: … etravirine … plus raltegravir 800 mg q24h. Viral resuppression was achieved on dolutegravir/rilpivirine …

Rationale: The study reports participants receiving the INSTIs raltegravir and dolutegravir.

Answer: Yes
"""

"""
Question: 4303 

Evidence: The patient was resuppressed under a dual therapy combining etravirine (400 mg q24h) and darunavir/ritonavir (800/100 mg q24h).

Rationale: Darunavir/ritonavir is a protease inhibitor regimen received by one individual.

Answer: Yes
"""

"""
Question: 4304 

Evidence: The two patients with adverse events … remained under etravirine/raltegravir dual therapy but as a q12h rather than a q24h regimen. Viral resuppression was achieved on dolutegravir/rilpivirine … + lamivudine … [other regimen changes described].

Rationale: Not all individuals remained on the same ART throughout; some changed regimens or dosing schedules.

Answer: No
"""

"""
Question: 4305 

Evidence: … under a stable oral dual etravirine/raltegravir therapy q12h for at least 96 weeks were eligible … They were switched … to … etravirine … plus raltegravir …

Rationale: All participants had been receiving the INSTI raltegravir before switching; thus they were not INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: One VF … resuppressed under … etravirine … and darunavir/ritonavir. The second VF … Viral resuppression was achieved on dolutegravir/rilpivirine … + lamivudine. The two patients with adverse events … remained … but as a q12h rather than a q24h regimen.

Rationale: At least four individuals are documented as receiving more than one ART regimen during the study: two VF cases who changed regimens and two AE cases who changed dosing regimens.

Answer: 4
"""

"""
Question: 4404 

Evidence: One VF … resuppressed … etravirine … and darunavir/ritonavir. The second VF … Viral resuppression was achieved on dolutegravir/rilpivirine … + lamivudine.

Rationale: The paper does not state that any individual received more than two distinct ART regimens during the study, and provides insufficient detail to determine this definitively.

Answer: NA
"""

"""
Question: 4405 

Evidence: The two patients with adverse events … remained under etravirine/raltegravir … but as a q12h rather than a q24h regimen. Viral resuppression was achieved on dolutegravir/rilpivirine … + lamivudine.

Rationale: Because some individuals changed regimens while others did not, the number of regimens per person varied.

Answer: No
"""

"""
Question: 4406 

Evidence: The two patients with adverse events … remained under etravirine/raltegravir … but as a q12h … The patient was resuppressed under … etravirine … and darunavir/ritonavir. Viral resuppression was achieved on dolutegravir/rilpivirine … + lamivudine.

Rationale: Several individuals received more than one regimen; therefore not all received only one ART regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Viral resuppression was achieved on dolutegravir/rilpivirine (50/25 mg q24h) + lamivudine (300 mg q24h).

Rationale: This statement indicates one individual received dolutegravir as part of a new regimen.

Answer: 1
"""

"""
Question: 4502 

Evidence: The patient was resuppressed under a dual therapy combining etravirine (400 mg q24h) and darunavir/ritonavir (800/100 mg q24h).

Rationale: This statement indicates one individual received darunavir/ritonavir.

Answer: 1
"""

"""
Question: 5101 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H). The second VF occurred at W48 … and no emergence of resistance.

Rationale: Only one individual is reported to have developed one or more resistance mutations during the study period.

Answer: 1
"""

"""
Question: 5102 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H).

Rationale: Only this single case had INSTI-resistance mutations.

Answer: 1
"""

"""
Question: 5103 

Evidence: One VF … leading to … INSTI … The second VF … no emergence of resistance.

Rationale: The paper does not report any tenofovir (TDF) resistance mutations.

Answer: NA
"""

"""
Question: 5104 

Evidence: One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs (L74I, G140A and Q148H).

Rationale: These are the specific INSTI-resistance mutations reported to have developed.

Answer: L74I, G140A, Q148H
"""

"""
Question: 6101 

Evidence: Secondary outcomes included … plasma drug concentrations and resistance profile in the case of VF. Plasma concentrations of etravirine and raltegravir were determined by UPLC … 

Rationale: The study did not perform phenotypic susceptibility testing; only pharmacokinetics and genotypic resistance were assessed.

Answer: NA
"""

"""
Question: 6102 

Evidence: Plasma concentrations of etravirine and raltegravir were determined by UPLC coupled with tandem MS … Etravirine and raltegravir C24h values were considered to be adequate if above the respective PBIC95.

Rationale: No IC50/IC90 values are reported.

Answer: No
"""

"""
Question: 6103 

Evidence: Plasma concentrations … were determined … interpretation was based on … PBIC95 … Etravirine 116 ng/mL … raltegravir 15 ng/mL.

Rationale: The paper does not report IC50 fold change values.

Answer: No
"""

"""
Question: 6104 

Evidence: Secondary outcomes included … plasma drug concentrations and resistance profile in the case of VF. Plasma concentrations … were determined by UPLC-MS/MS.

Rationale: No phenotypic susceptibility assay is described.

Answer: NA
"""

"""
Question: 6105 

Evidence: Clinical data, pVLs and safety parameters … were collected … Secondary efficacy endpoints included … the incidence of genotypic resistance … and the antiretroviral drug concentration …

Rationale: Replication capacity measurements are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: Plasma concentrations of etravirine and raltegravir were determined by UPLC-MS/MS. One VF … resuppressed under … darunavir/ritonavir … The second VF … resuppression … dolutegravir/rilpivirine + lamivudine.

Rationale: No phenotypic susceptibility testing was performed; hence no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Patients … were switched … in this prospective … clinical study. One VF occurred at W24 … leading to the emergence of resistance mutations associated with INSTIs …

Rationale: The paper reports clinical isolates/mutations from patients; no site-directed mutants are described.

Answer: No
"""

"""
Question: 7102 

Evidence: Patients … were switched … in this prospective … study. Clinical data … and resistance profile in the case of VF … were collected.

Rationale: No in vitro passage experiments were conducted or reported.

Answer: No
"""